PMID- 34210406
OWN - NLM
STAT- MEDLINE
DCOM- 20211125
LR  - 20211125
IS  - 2667-2960 (Electronic)
IS  - 2667-2960 (Linking)
VI  - 62
IP  - 4
DP  - 2021 Jul-Aug
TI  - Psychedelic Psychiatry and the Consult-Liaison Psychiatrist: A Primer.
PG  - 460-471
LID - S2667-2960(20)30014-8 [pii]
LID - 10.1016/j.jaclp.2020.12.011 [doi]
AB  - BACKGROUND: Psychedelic compounds such as lysergic acid diethylamide (LSD), 
      psilocybin, and 3,4-Methylenedioxymethamphetamine (MDMA) share a long and complex 
      history with psychiatry. A half century ago, psychedelics were widely employed by 
      psychiatrists in investigational and clinical settings, with studies 
      demonstrating promising findings for their use in the treatment of mental illness 
      and substance use disorders. However, concerns were also raised about their abuse 
      potential and other adverse effects. Owing to these worries and psychedelics' 
      association with the counterculture movement, psychedelics were largely outlawed 
      in the United States in 1970, bringing research on their therapeutic potential to 
      a halt. However, in recent years, a resurgence of psychedelic research has 
      revealed compelling, though early, evidence for the use of psychedelic-assisted 
      therapy in treating alcohol use disorder, nicotine use disorder, posttraumatic 
      stress disorder, and depression. OBJECTIVE: Here we provide an overview of 
      psychiatry's complicated relationship with psychedelics, while reviewing 
      contemporary findings on psychedelic-assisted therapy, safety of 
      psychedelic-assisted therapy, and risks of nonmedical use. We also make the case 
      that psychiatry should consider preparing now for the possibility of Food and 
      Drug Administration approval of psychedelic-assisted therapies in the near 
      future. We conclude by discussing how growing societal interest in psychedelics 
      could impact the work of consult-liaison psychiatrists, while also exploring how 
      consult-liaison psychiatrists might contribute to future delivery of psychedelic 
      treatments. METHODS: We reviewed literature on psychedelic-assisted therapies and 
      adverse events resulting from nonmedical psychedelic use. RESULTS: We found a 
      small, but rapidly growing literature indicating that psychedelic-assisted 
      therapies may have treatment potential for mental illness and addiction. Our 
      search also revealed a variety of rare adverse events stemming from nonmedical 
      psychedelic use. CONCLUSIONS: Despite past concerns about psychedelics, current 
      data indicate psychedelic-assisted therapy may potentially reduce suffering owing 
      to mental illness and addiction if administered thoughtfully and cautiously by 
      trained professionals in medical settings.
CI  - Copyright (c) 2021 Academy of Consultation-Liaison Psychiatry. Published by 
      Elsevier Inc. All rights reserved.
FAU - Barnett, Brian S
AU  - Barnett BS
AD  - Department of Psychiatry and Psychology, Center for Behavioral Health, 
      Neurological Institute, Cleveland Clinic, Cleveland, OH. Electronic address: 
      barnetb3@ccf.org.
FAU - Greer, George R
AU  - Greer GR
AD  - Heffter Research Institute, Greenwich, CT.
LA  - eng
PT  - Journal Article
DEP - 20210121
PL  - Netherlands
TA  - J Acad Consult Liaison Psychiatry
JT  - Journal of the Academy of Consultation-Liaison Psychiatry
JID - 101775059
RN  - 0 (Hallucinogens)
RN  - 2RV7212BP0 (Psilocybin)
RN  - 8NA5SWF92O (Lysergic Acid Diethylamide)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - *Hallucinogens/adverse effects
MH  - Lysergic Acid Diethylamide
MH  - *N-Methyl-3,4-methylenedioxyamphetamine
MH  - Psilocybin/adverse effects
MH  - *Psychiatry
MH  - United States
EDAT- 2021/07/03 06:00
MHDA- 2021/11/26 06:00
CRDT- 2021/07/02 05:42
PHST- 2020/09/20 00:00 [received]
PHST- 2020/12/26 00:00 [revised]
PHST- 2020/12/27 00:00 [accepted]
PHST- 2021/07/02 05:42 [entrez]
PHST- 2021/07/03 06:00 [pubmed]
PHST- 2021/11/26 06:00 [medline]
AID - S2667-2960(20)30014-8 [pii]
AID - 10.1016/j.jaclp.2020.12.011 [doi]
PST - ppublish
SO  - J Acad Consult Liaison Psychiatry. 2021 Jul-Aug;62(4):460-471. doi: 
      10.1016/j.jaclp.2020.12.011. Epub 2021 Jan 21.